ClinicalTrials.govpublic full text
Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer
breast cancer, her2-positive breast cancer, pathologic complete response, dalcelli, objective response rate, disease-free survival, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 888158
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.